Evidence supporting the use of: Lactobacillus brevis
For the health condition: Allergies (respiratory)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus brevis, a probiotic bacterium, has attracted interest for its potential role in modulating immune responses, including those involved in respiratory allergies such as allergic rhinitis and asthma. The scientific basis for its use is still emerging, and current evidence is limited but promising. Some animal studies and small-scale human trials have suggested that L. brevis may help regulate the immune system by promoting the production of anti-inflammatory cytokines (such as IL-10) and reducing pro-inflammatory responses. These immunomodulatory effects could theoretically reduce allergic symptoms by balancing the Th1/Th2 response, which is often skewed in allergic individuals.

One key study published in Allergy (2012) demonstrated that oral administration of L. brevis in mice reduced airway inflammation and IgE levels, markers associated with respiratory allergies. Limited clinical data in humans also suggest a possible reduction in symptoms and improvement in quality of life for allergy sufferers, though studies are often small and heterogeneous in design.

Despite these encouraging findings, the overall level of evidence remains low (rated 2/5), primarily due to limited sample sizes, lack of large-scale randomized controlled trials, and variability in probiotic strains and formulations. More robust clinical research is needed to confirm efficacy and establish guidelines for use. Therefore, while the use of Lactobacillus brevis for respiratory allergies is supported by preliminary scientific findings, it should be considered as an adjunct rather than a primary therapy.

More about Lactobacillus brevis
More about Allergies (respiratory)